Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

  • Revenue in USD (TTM)52.79bn
  • Net income in USD22.98bn
  • Incorporated1996
  • Employees108.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NOVN:SWX since
announced
Transaction
value
Gyroscope Therapeutics Holdings PLC(WAS 4L1215)Deal completed22 Dec 202122 Dec 2021Deal completed0.93%1.50bn
Alnylam Pharmaceuticals IncRumoured18 Nov 202118 Nov 2021Rumoured5.09%--
Arctos Medical AGDeal completed21 Sep 202121 Sep 2021Deal completed3.74%--
Data delayed at least 15 minutes, as of Aug 12 2022 16:31 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.